

Docket No. 57094 (71526)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: M. Sakanaka et al.

Serial No.: Not Yet Assigned

Filed: Herewith

For: BRAIN CELL OR NERVE CELL-PROTECTING AGENTS COMPRISING
MEDICINAL GINSENG

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

In accordance with the provisions of 37 C.F.R. §§1.56 and 1.97, Applicants herewith submit the publications and/or patents shown on the attached form PTO-1449, for consideration by the Examiner in connection with the examination of the above-identified patent application.

REMARKS

In accordance with the provisions of 37 C.F.R. §1.97, this statement is being filed:

- X (1) within three (3) months of the Filing Date or **before the mailing date of the First Office Action** on the merits; or
- (2) within three months of the mailing date of the Written Opposition issued by the: _____ Patent Office (dated _____); or
- (3) after the period defined in (1) but before the mailing date of a Final Rejection or Notice of Allowance, and the requisite Certification or fee under Rule 1.17(p), namely \$240.00, is included herein; or
- (4) after the mailing date of a Final Rejection or Notice of Allowance but before the payment of the Issue Fee, and the requisite Certification, petition, and petition fee are included herein.

It is respectfully requested that each of the documents shown on the attached form(s) PTO-1449 be made of record in this application. Copies of these documents (CHECK ONE):

Applicants: M. Sakanaka et al.
Serial No.: Not Yet Assigned
Page 2


X are enclosed herewith; or
— have been cited in the parent application, and are thus not being resubmitted
herein.

Early examination and allowance of the present application are respectfully solicited.

FEE AUTHORIZATION

Should any fees associated with the submission be required, the Commissioner is authorized to charge the missing fee to our Deposit Account, No. 04-1105. Any overpayments should be credited to said Deposit Account.

Respectfully submitted,



Peter F. Corless (Reg. 33,860)
EDWARDS & ANGELL, LLP
P.O. Box 9169
Boston, MA 02209
(617) 439-4444

Date: February 28, 2002

FORM PTO-1449				DOCKET NO.: 57094 (71526)		SERIAL NO.: Not Yet Assigned	
INFORMATION DISCLOSURE STATEMENT				APPLICANT(S): M. Sakanaka et al.			
				FILING DATE: Herewith		GROUP NO.:	
UNITED STATES PATENT DOCUMENTS							
EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO
	AA	2000-159793	06/13/00	Japan			No
	AB	6-316527	11/15/94	Japan			No
	AC	4-504414	08/06/92	Japan			No
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)							
	AD	Acta Pharmaceutica Sinica 32(6):406-410 (1997).					
	AE	Korean J. Ginseng Sci., 22(1):66-72 (1998).					
	AF	Acta Pharmacologica Sinica, 17(1):44-48 (1996).					
	AG	Neuroscience Research, 28:191-200 (1997).					
	AH	Acta Pharmaceutica Sinica, 30(9):674-678 (1995).					
	AI	Chinese Journal of Pharmacology and Toxicology 8(1): 7-12 (1994).					
	AJ	Chinese Journal of Pharmacology and Toxicology 3(1)::18-23 (1939).					
	AK	Acta Pharmacologica Sinica, 13(5):403-406 (1992).					
	AL	Acta Pharmacologica Sinica, 7(3):222-226 (1986).					
	AM	Clinical and Experimental Pharmacology and Physiology, 23:728-732 (1996).					
	AN	Acta Pharmaceutica Sinica, 22(1):1-5 (1987).					
	AO	Chem. Pharm. Bull (21(13):2702-2711 (1973).					
	AP	Chemical & Pharmaceutical Bulletin, 40(2):299-564 (1992).					
Examiner:					Date:		